A phase II trial of dasatinib (D) in combination with trastuzumab (T) and paclitaxel (P) in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients (pts): GEICAM/2010-04 [PDF]
, 2017 A. Ocana Fernandez +19 more
openalex +1 more source
The Synthesis and Anticancer Activity of the Trastuzumab-Doxorubicin Antibody-Drug Conjugate Using Strain-Promoted Alkyne-Azide Coupling. [PDF]
ACS OmegaThakur SK +4 more
europepmc +1 more source
Cancer Medicine, Volume 15, Issue 3, March 2026.ABSTRACT Gastric cancer remains a leading cause of cancer‐related mortality worldwide, with locally advanced gastric/gastroesophageal junction adenocarcinoma posing significant therapeutic challenges. Neoadjuvant therapy has emerged as a critical strategy to improve surgical outcomes and long‐term survival by reducing tumor burden and eradicating ...
Jiaqi Zhou +7 more
wiley +1 more source
Long-term responders to trastuzumab monotherapy in the first-line metastatic setting: characteristics and survival data (SAKK 22/99 Trial) [PDF]
, 2017 Sabine Schmid +15 more
openalex +1 more source
A real-world comparison study of the efficacy of dual-target first-line rescue treatment of human epidermal growth factor receptor 2 positive advanced breast cancer: trastuzumab combined with pertuzumab versus trastuzumab combined with pyrotinib. [PDF]
Front OncolZhang L +7 more
europepmc +1 more source
CRISPR Assays for Protein Detection
Chemistry–Methods, Volume 6, Issue 3, March 2026.This review summarizes recent advances in CRISPR–Cas–based strategies for protein detection. Particular focus is placed on recognition element–based approaches, in which antibodies, aptamers, or DNAzymes convert protein binding into CRISPR‐readable nucleic acid signals, and activity‐based strategies that exploit intrinsic protein functions to trigger ...
Luca Capelli +5 more
wiley +1 more source
'Patients are left not knowing': Trastuzumab (Herceptin) cardiac risk information and management in HER2-positive breast cancer-a qualitative study of patient experience. [PDF]
Support Care CancerDolgilevica K, Chapman B, Derakshan N.
europepmc +1 more source
High accuracy in detecting HER2‐low status in FNA of primary and metastatic breast cancer
Cancer Cytopathology, Volume 134, Issue 3, March 2026.ABSTRACT Background HER2‐positive invasive breast carcinomas (IBCs) account for 15% of breast cancers and are driven by ERBB2 gene amplification. Although historically associated with aggressive behavior, HER2‐targeted therapies have significantly improved outcomes.
Giuseppe D’Abbronzo +11 more
wiley +1 more source
Real-World Outcomes of First-Line Pertuzumab, Trastuzumab, and Taxane in HER2-Positive Metastatic Breast Cancer in Costa Rica: A Multicenter Retrospective Study. [PDF]
CureusPriyanka K, Landaverde DU.
europepmc +1 more source